HMGCR and bacterial pneumonia: Given that HMG-coA reductase inhibitors (i.e. statins) decrease hsCRP in the general population [39] and in patients with HIV infection [40], [41] and given that statins have been associated with possible decreased bacterial pneumonia risk [42], we included lipid-lowering therapy in a multivariate model.